English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Oritavancin exhibited potent activity against vancomycin-susceptible (MIC50 and MIC90 , 0.015/0.03 μg/ml) andvanB -carryingE. faecalis isolates (MIC50 and MIC90 , 0.015 and 0.015 μg/ml). Higher (16- to 32-fold) MIC50 s and MIC90 s forvanA -harboringE. faecalis were noted (MIC50 and MIC90 , 0.25 and 0.5 μg/ml), although oritavancin inhibited all strains at ≤0.5 μg/ml. Vancomycin-susceptible andvanB -carryingE. faecium strains (MIC50 and MIC90 , ≤0.008 and ≤0.008 μg/ml for both) were very susceptible to oritavancin, as were VanA-producing isolates (MIC50 and MIC90 , 0.03 and 0.06 μg/ml). Oritavancin exhibited goodin vitro potency against this collection of organisms, including vancomycin-resistant enterococci.

antimicrobial agents and chemotherapy

Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010